TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin for Pelvic Pain in Women With Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Female gender~* Age between 18 and 55~* History of endometriosis at surgery~* Persistent pelvic pain for at least 3 months~* Pelvic floor spasm~* Negative pregnancy test (in women who have not had a hysterectomy)~* Willing to use reliable method of contraception for the month after botulinum toxin injection including oral contraceptives, IUD, and barrier with spermicide.~* Willing and able to give informed consent~* Willing and able to comply with study requirements~EXCLUSION CRITERIA:~* Women with other causes of chronic pelvic pain including infectious, gastrointestinal, psychological disorders, fibromyalgia and chronic fatigue syndrome based on review of medical history within 1 year of first study visit,~* Untreated severe cervical dysplasia or other gynecologic condition clinically significant abnormalities on physical or laboratory examinations that require evaluation or treatment or that would make participation unsafe~* Hysterectomy and bilateral salpingo-oophorectomy~* Pregnancy~* Lactation~* Allergy to albumen or botulinum toxin~* Presence of antibodies to botulinum toxin or loss of response to previous injections for any indication~* A known neuromuscular junction disorder such as myasthenia gravis or Eaton-Lambert syndrome~* History of urinary or fecal incontinence~* Known pelvic prolapse~  * Eligibility will be based on a physical exam at NIH at the first study visit, as well as history and available medical records within 1 year before the study visit. Negative test results will be documented to confirm study eligibility. If the Pap and the GC and chlamydia tests were not done outside of the NIH within the previous year, or if documentation of the negative test results is not available, we will await the results of the screening tests done at the NIH before administering the study medication.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Botulinum toxin (BoNT) (Type: EXPERIMENTAL): OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration
- Placebo (Type: PLACEBO_COMPARATOR): Saline, 4cc, one time intramuscular administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adalimumab for Inflammatory Osteoarthritis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is 40 years of age or older.~* If female, patient is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of birth control: condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD) contraceptives (oral or parenteral) for three months prior to study drug administration),a vasectomized partner, total abstinence from sexual intercourse~* If patient is female and of childbearing potential, the results of a serum pregnancy test performed at Screening, prior to the first dose of adalimumab, must be negative.~* Patient has a diagnosis of OA of the index knee according to American College of Rheumatology criteria, including radiological evidence of OA (Kellgren-Lawrence grades 2 or 3).~* Patient has had continual pain for at least 6 months prior to inclusion in the study. This includes pain that has persisted despite conventional treatment, defined as any one of the following medications taken daily during the preceding month:acetaminophen (2- 4 grams per day)maximum tolerated and recommended doses of an NSAID, acetaminophen/codeine combination (i.e. Tylenol No 2, 3, 4) taken at least 3 times daily~* Patient has had daily knee pain for the month preceding study enrolment.~* Patient has a summed pain score of 125-400mm (visual analog scale) on the WOMAC pain sub-scale in the index (more symptomatic) knee.~* Patient has clinical evidence of a knee effusion in the index (more symptomatic) knee at Screening and Baseline.~Exclusion Criteria:~* Subject has a history of an allergic reaction or significant sensitivity to constituents of Adalimumab.~* Patient has a history of proven systemic arthritis such as rheumatoid arthritis.~* Patient has a concurrent medical or arthritic condition that could confound evaluation of the index joint e.g. post-traumatic or any secondary form of knee OA~* Patient has predominant patellofemoral disease

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- adalimumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. M/F patients 18 years of age or older~2. Diagnosis of ESRD (GFR ≤ 15 mL/min)~3. CAPD or APD using only Dianealand/or Physioneal, at least 1 exchange of 2.5% or 4.25% dextrose/day, no prescribed dry time~4. DM (Type 1 and 2) on glycemic-control medication, for 90 days~5. HbA1c \> 6.0% but ≤ 12.0%~6. Blood hemoglobin ≥ 8.0 g/dL, but ≤ 13.0 g/dL~Exclusion Criteria:~1. Cardiovascular event within the last 90 days~2. Ongoing clinically significant congestive heart failure (NYHA class III or IV)~3. Allergy to starch-based polymers~4. Glycogen storage disease~5. Maltose, or isomaltose intolerance~6. Peritonitis, exit-site or tunnel infection treated with antibiotics within last 30 days~7. Mean Arterial Pressure (MAP) ≥ 125 mm Hg, or volume depleted (MAP \< 77) at Screening.~8. Serum urea \> 30 mmol/L~9. Exposure to Extraneal or Nutrineal within the last 60 days prior to Screening visit, Day 1.~10. Receiving rosiglitazone maleate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non glucose sparing (Type: ACTIVE_COMPARATOR): Dianeal only
- glucose sparing (Type: EXPERIMENTAL): PEN solutions: Nutrineal, Extraneal, and Physioneal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tiotropium / Respimat One-Year Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Criteria~* Patients with stable moderate to severe COPD and a smoking history of at least 10 pack years were eligible for inclusion in the study. Patients with significant diseases other than COPD were excluded as were patients with a recent history of myocardial infarction, history of malignancy, unstable or life-threatening cardiac arrhythmia, narrow-angle glaucoma, asthma or other allergic conditions. Patients treated with cromolyn, nedocromil, oral beta-adrenergics or unstable doses of oral corticosteroids were ineligible for inclusion in the study as were patients who had received previous treatment with tiotropium.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tiotropium Respimat 5mcg (Tio R5) (Type: OTHER): None
- Tiotropium Respimat 10mcg (Tio R10) (Type: OTHER): None
- Placebo (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Multiple Sclerosis With Copaxone and Albuterol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Patients may be eligible for this study if they:~* Have been diagnosed with RR-MS, within 2 years of diagnosis.~* Are 18-55 years old.~* Have RR-MS with evidence of demyelination on MRI scanning of the brain.~* Have extended disability status scale (EDSS) scores between 0 and 3.5.~* Have not taken Copaxone or oral myelin.~* Have not had immunomodulating therapy for the past 3 months.~* Have not taken immunosuppressants.~* Have not had steroid treatment 1 month before entry.~* Have no evidence of active infection or cancer.~Exclusion Criteria~Patients may not be eligible for this study if they:~* Have a normal brain MRI.~* Are not willing to practice contraception (applies to women who are able to have children).~* Are pregnant or breast-feeding.~* Are currently taking any of the following drugs: beta2-adrenergic agonist or antagonist, diuretics, tricyclic antidepressants, or monoamine oxidase inhibitors.~* Have heart, blood, liver, or kidney problems.~* Have a disease that affects blood clotting or lung function.~* Have abnormalities that relate to the endocrine system.~* Have a history of alcohol or drug abuse within 6 months of enrollment.~* Have been diagnosed with primary progressive MS, in which the disease slowly worsens without periods of recovery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will receive Copaxone and albuterol placebo
- 2 (Type: EXPERIMENTAL): Participants will receive Copaxone and albuterol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of ALKS 3831 in Adults With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 50 years, inclusive~* Body mass index (BMI) of 17-30 kg/m2, inclusive~* Diagnosis of schizophrenia that is clinically stable~Exclusion Criteria:~* Initiated 1st antipsychotic treatment within the past 12 months and/or has had symptoms lasting \<2 years~* Current diagnosis of alcohol or drug use disorder, moderate or severe~* Clinically significant or unstable medical illness, condition, or disorder~* Pregnant or breastfeeding~* Significant changes in diet or exercise regimen or plans to join a weight management program during the study~* Opioid medications taken within 14 days and/or need to take opioid medication during the study period~* History of hypersensitivity to or intolerance of olanzapine~* Use of olanzapine, clozapine, mesoridazine, chlorpromazine, or thioridazine for more than 1 week during the past year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose (Type: EXPERIMENTAL): Olanzapine + low dose samidorphan tablets taken once daily
- Medium Dose (Type: EXPERIMENTAL): Olanzapine + medium dose samidorphan tablets taken once daily
- High Dose (Type: EXPERIMENTAL): Olanzapine + high dose samidorphan tablets taken once daily
- Placebo (Type: PLACEBO_COMPARATOR): Olanzapine + placebo tablets taken once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Either gender and Age ≥ 50.~* Naïve PCV patients.~* Confirmed diagnosis of symptomatic macular PCV in the study eye.~* Greatest linear dimension of the lesion of \< 5400 mm, assessed by ICG angiography.~* BCVA at study entry of 25 to 80 letters (Snellen Equivalent 20/320 to 20/25).~* Lesion size in the study eye at study entry:~* Presence of PCV assessed by the Central Reading Centre based on ICG with active polyps with or without abnormal vascular network.~* Women must be using effective contraception, be post-menopausal for at least~* months prior to trial entry, or surgically sterile.~* Ability to provide written informed consent.~* Ability to return for all study visits.~Exclusion Criteria:~* Active inflammation or infection in the study eye.~* Uncontrolled intraocular pressure in the study eye.~* Ocular condition in the study eye which may impact vision and confound study outcomes (e.g. vitreomacular traction, epirretinal membrane with BCVA impact, ocular inflammation, retinal vascular diseases like diabetic retinopathy or diabetic macular edema).~* Presence of centromacular scarring or atrophy indicating irreversible BCVA loss.~* Prior treatment of the study eye with anti-VEGF therapy or systemic use of anti-VEGF products within 3 months prior to the study entry.~* Previous vitrectomy, macular laser treatment, PDT, or intraocular steroids in the study eye.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Aflibercept Monotherapy (Type: SHAM_COMPARATOR): IVT Aflibercept 2 mg + Sham PDT
- Aflibercept + verteporfin PDT (Type: ACTIVE_COMPARATOR): IVT Aflibercept 2 mg + Verteporfin PDT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological or cytological diagnosis of lung adenocarcinoma histology with brain metastases~2. 18 years or older~3. Eastern Cooperative Oncology Group (ECOG) Performance Status no more than 3 (poor PS caused by neurological symptom)~4. Appraisable intracranial disease, the presence of at least one lesion, and the longest diameter \> 5 mm by brain MRI~5. Haemoglobin 10.0 g/dl, Absolute neutrophil count (ANC) 1.5\^9/L, platelets 100 x 10\^9/L~6. Total bilirubin 1.5 x upper limit of normal (ULN)~7. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 x ULN in the absence of liver metastases, or \< 5 x ULN in case of liver metastases~8. Creatinine clearance 60ml/min (calculated according to Cockcroft-gault formula)~9. If received brain radiotherapy, patients included at least 8 weeks after the end of radiotherapy.~Exclusion Criteria:~1. Mixed non-adenocarcinoma cell lung cancer histology~2. Previous treatment with pemetrexed or tarceva~3. Be allergic to pemetrexed or tarceva

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib, pemetrexed, cisplatin (Type: EXPERIMENTAL): None
- erlotinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Chronic HCV infected genotype 1, 2 (Taiwan only), 4, 5, or 6 male and nonpregnant/ nonlactating females aged 18 years or older who are on dialysis for ESRD, including adults with HIV coinfection if they are suppressed on a stable, protocol-approved antiretroviral (ARV) regimens for ≥8 weeks prior to screening.~NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF for 8 weeks (Type: EXPERIMENTAL): Treatment-naive participants with genotype 1 without cirrhosis will receive LDV/SOF for 8 weeks
- LDV/SOF for 12 weeks (Type: EXPERIMENTAL): Treatment-experienced participants with genotype 1 and treatment-naive or treatment-experienced participants with genotype 2 (Taiwan only), 4, 5 and 6 without cirrhosis will receive LDV/SOF for 12 weeks
- LDV/SOF for 24 weeks (Type: EXPERIMENTAL): Participants with compensated cirrhosis will receive LDV/SOF for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~1. Patients with essential hypertension whose blood pressure is not adequately controlled by amlodipine or telmisartan monotherapy (=140/90 mmHg, = 130/80 mmHg for those with diabetes or kidney disease)~2. Age = 19 years at enrollment~3. Male or female patient (or legally acceptable representative) willing and able to provide written informed consent~Exclusion criteria:~1. Patients with previous exposure to Twynsta~2. Patients with hypersensitivity to the active substances, or to dihydropyridine derivatives~3. Female patients at second and third trimesters of pregnancy~4. Female patients with lactation~5. Patients with biliary obstructive disorders~6. Patients with severe hepatic impairment~7. Patients with high grade aortic stenosis~8. Patients with shock~9. Patients with hereditary conditions such as intolerance with excipient of the products~10. Current participation in other clinical trials or observational studies

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with essential hypertension (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zinc Supplement in Regorafenib Treated mCRC Patient

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib~* Ability to understand and willingness to sign written Informed Consent Form (ICF)~Exclusion Criteria:~* Patients participating in an investigational program with interventions outside of routine clinical practice~* Patients with baseline Zinc level above 120 ug/dL~* Patients with known allergy to Zinc supplementation~* Pregnancy~* Patients who are unsuitable for study participation, based on investigator's discretion

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regorafenib treatment with Zn supplement (Type: EXPERIMENTAL): Patients enrolled in this arm received regorafenib with zinc supplementation to examine if zinc supplementation can decrease the incidence of grade 2 or higher HFSR.
- Regorafenib treatment only (Type: ACTIVE_COMPARATOR): Patients enrolled in this arm received regorafenib without zinc supplementation, which is the standard treatment of patients of metastatic colorectal cancer who failed previous standard therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of idiopathic Parkinson's Disease,~* advance stage of disease,~* Modified Hoehn \& Yahr stage II-IV,~* presence of a recognizable 'on' and 'off' state (motor fluctuations) and stable treatment with levodopa for at least 28 days prior to randomization~Exclusion Criteria:~* 'on-off' phenomena or 'yo-yoing' and/or an abrupt unpredictable loss of efficacy unrelated to the timing of L-DOPA administration,~* Prevalent expression of troublesome dyskinesias during 'on' time at waking hours,~* Diagnosis is unclear or a suspicion of other parkinsonian syndromes exists,~* Previous surgery for the treatment of PD

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete